Company
 

History

2000
Formation of Proteo Biotech AG, spin-off of the University of Kiel, Germany
Proteo Biotech AG entered into a reorganization and stock exchange agreement with Proteo, Inc., USA, and as a result Proteo Biotech AG became a wholly owned subsidiary of Proteo, Inc.
2001
State of Schleswig-Holstein funds Elafin development project of Proteo Biotech AG.
Development of Elafin production under laboratory conditions with competent biotechnology enterprises
2002
Proteo granted approval to operate gene technology facility
First marketing activities with the Dutch biotech-company HyCult Biotechnology B.V.
2003
Successful completion of studies on acute toxicity of Elafin in mice and rats
Official inauguration of the Proteo Biotech plant in Kiel
2004
An additional 760.000 EUR funding has been provided through an European regional development program ( EFRE) for further development of Elafin.
Research-Collaboration-Agreement between the Charité Berlin and Proteo Biotech AG
Exclusive License- and Collaboration- Agreement with Artes Biotechnology GmbH for an expression technology
2005
First Production of Elafin for clinical testing
Elafin was successfully tested in a Phase I clinical trial.
2006
Strategic alliance for marketing of Elafin in Asia, Africa and South America with Artes Biotechnology GmbH
Elafin ranked as a Top 10 Cardiovascular Drug Development
2007
European Commission grants Orphan Drug Status to Elafin for the treatment of PAH.
Proteo cooperates with the University of Alberta.
Proteo and Minapharm, Egypt, entered into a license agreement for clinical development, production and marketing of Elafin in Egypt, Middle Eastern and African countries.
2008
Proteo cooperates with Stanford University.
Start Phase II clinical trial with Elafin in patients undergoing esophagectomy for esophagus carcinoma
2009
Cooperation with the University of Edinburgh to investigate the effect of Elafin on the damage and inflammation of cardiac muscle after coronary bypass operations in a Phase II clinical trial
Clinical study in Harvard reveals Elafin deficiency in acute respiratory distress syndrome (ARDS).
2010
European Commission grants Orphan Drug Designation for the protease inhibitor Elafin for the treatment of oesophagus carcinoma.
Successful completion of patient recruitment for the Phase II clinical trial on Elafin in patients with esophagus cancer
Proteo cooperates with Molecular Imaging North Competence Center (MOIN CC).
The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) tested Proteo’s Elafin.
2011
Results Phase II clinical trial: Elafin shortens intensive care after surgery for esophagus cancer
Start Phase II clinical trial with Elafin in patients undergoing coronary bypass surgery
NIH supports the Elafin development program for lung diseases at Stanford University with a $10.8 million grant.
2012
75% of subjects recruited for the Phase II clinical trial on Elafin in patients undergoing coronary bypass surgery
2013
FDA grants Orphan Drug Designation for Elafin for the treatment of pulmonary arterial hypertension.
FDA grants Orphan Drug Designation for Elafin for the prevention of inflammatory complications of transthoracic esophagectomy.
Patient recruitment for the Phase II clinical trial on Elafin in patients undergoing coronary bypass surgery completed
2014
$ 4.8 million funding for Proteo's Advanced Orphan Drug Development
Results Phase II clinical trial in patients undergoing coronary bypass surgery: Significant reduction of cardiac troponin I within first 6 hours after Elafin treatment. The favorable safety profile of Elafin was confirmed. Statistical significance on the primary endpoint could not be demonstrated.
2015
In a mouse model, Elafin and cyclosporine A act synergistically to prevent the development of irreversible damage to transplanted lung tissue.
Elafin reverses obliterative changes in explanted lung tissue from PAH patients.
In December, the EMA paediatric committee (PDCO) adopted a positive opinion regarding Proteo's application for a product-specific paediatric investigation plan (PIP) waiver for Tiprelestat in the treatment of oesophageal carcinoma.

http://proteo.de/pages/company/history.html – printed on 2017-05-16 11:44:07